(Aditya Shaw, Intern Journalist): The last trial of the indigenous corona vaccine Covaxin may begin next month. Bharat Biotech has got permission for a Phase 3 trial from the drug regulator. DCGI’s expert committee met on Tuesday. In this, approval of the last trial of the vaccine was given. DCGI has ‘slightly modified’ the protocol. More than 25 thousand people are expected to participate in vaccine trials in India. They will be given two doses of vaccine at an interval of 28 days. The results of the vaccine in the initial trial have raised hopes. Covaxin is the first indigenous coronavirus vaccine. It has been created in association with the Indian Council of Medical Research (ICMR).
A meeting of the committee was held on 5 October. In it, the company was asked to resubmit the phase-3 trial protocol. The committee believed that the design of the Phase-3 study was satisfactory. But it should start after determining the right dose from Phase-2 safety and immunogenicity data. The committee demanded that data before the firm.
Bharat Biotech plans that the last trial of Covaxin is done in addition to Delhi in Uttar Pradesh, Bihar, Maharashtra, Punjab, and Assam. The company is expecting the final trial results by February. After that, approval will be applied for approval and marketing.
Bharat Biotech has added an Adjuvant named Alhydroxiquim-II to its Covid vaccine. This will improve the immunodeficiency of vaccines and it will provide long-term protection from the corona. An adjuvant is an agent that increases the efficiency of the vaccine when added. This creates more antibodies in the body after being vaccinated and provides longer-term immunity.
Apart from Covaxin, two more Corona vaccines are undergoing trials in India. Serum Institute of India (SII) has partnered with Oxford-AstraZeneca in the vaccine. The company is testing its vaccine ‘Covishield’ in the country. In addition, Zydus Cadila has developed a vaccine called ZyCov-D. Many other companies are also doing research. Some have also made deals with vaccines from foreign companies.
About Post Author
